Carbapenem-Based Antibiotics Market Report 2026

The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.78 billion in 2025 to $5.03 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing prevalence of bacterial infections, advancements in antibiotic formulations, growing awareness of nosocomial infections, rising geriatric population, expansion of hospital networks.

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to emergence of multidrug-resistant bacteria, development of combination therapies, expansion of healthcare access in emerging markets, adoption of precision medicine approaches, investment in novel carbapenem derivatives. Major trends in the forecast period include rising antibiotic resistance, increasing hospital-acquired infections, expansion of hospital infrastructure, growth in surgical procedures, demand for pediatric and geriatric antibiotics.

The rising occurrence of bacterial infections is anticipated to drive the growth of the carbapenem-based antibiotics market in the coming years. Bacterial infections are caused by bacteria, which are microscopic organisms capable of entering the body and triggering a wide variety of illnesses and symptoms. Carbapenem-based antibiotics are used to treat serious or multidrug-resistant bacterial infections, including those caused by both gram-positive and gram-negative bacteria. For example, in July 2024, a report released by the Centers for Disease Control and Prevention, a US-based government agency, stated that in 2023, 78% of all bacterial infections in the historic catchment area were diagnosed using culture-independent diagnostic tests (CIDTs), with 46% identified exclusively through CIDTs. As a result, the growing incidence of bacterial infections is fueling the expansion of the carbapenem-based antibiotics market.

Leading companies operating in the carbapenem-based antibiotics market are adopting innovative financial and distribution strategies to maintain their market position and promote antibiotic stewardship. Subscription-based models are designed to separate revenue generation from sales volume, thereby supporting responsible antibiotic use while maintaining financial sustainability for pharmaceutical manufacturers. For instance, in August 2024, the National Health Service (NHS), a UK-based government department, introduced a groundbreaking subscription program in partnership with the pharmaceutical industry to address antimicrobial resistance (AMR). Under this model, drug manufacturers receive fixed annual payments of up to $23.12 million (£20 million) per drug, regardless of prescription volume, eliminating incentives for excessive use. Estimated at around £1.9 billion over 16 years, the initiative seeks to encourage the development of new antibiotics, including carbapenems, by ensuring economic stability for drug developers. The NHS focuses on treatments targeting critical pathogens identified by the World Health Organization, underscoring its commitment to responsible antibiotic use while supporting innovation in antibiotic development.

In July 2023, Melinta Therapeutics LLC, a US-based commercial-stage company that manufactures carbapenem-based antibiotics, entered into a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance FDA-approved antibiotics. As part of this collaboration, BARDA provided $20.5 million in initial funding, with the potential to increase total support to $141.9 million if all options are exercised, enabling Melinta to progress four supplemental new drug applications (sNDAs) for expanded indications. BARDA is a US-based government agency that supports the development of medical countermeasures.

Major companies operating in the carbapenem-based antibiotics market are Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, Teva Pharmaceutical Industries Ltd., Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co. Ltd., ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation.

North America was the largest region in the Carbapenem-Based Antibiotics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the carbapenem-based antibiotics market by increasing the cost of imported raw materials and active pharmaceutical ingredients, leading to higher production expenses. Segments such as meropenem and imipenem are most affected, especially in regions like Asia-Pacific and Europe, which rely heavily on global supply chains. While tariffs create cost pressures, they also encourage local manufacturing and innovation in antibiotic synthesis, potentially enhancing domestic production capabilities and market resilience.

The carbapenem-based antibiotics market research report is one of a series of new reports that provides carbapenem-based antibiotics market statistics, including carbapenem-based antibiotics industry global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Carbapenem-based antibiotics represent a group of broad-spectrum antibacterial agents that are highly effective in treating a wide range of bacterial infections. These antibiotics are widely used for managing severe infections caused by both gram-positive and gram-negative bacteria, including strains that show resistance to other classes of antibiotics.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem is a broad-spectrum antibacterial agent that works by inhibiting bacterial cell wall synthesis to combat infections. It is commonly prescribed for treating serious bacterial conditions such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics are used in the treatment of intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, surgical site infection prophylaxis, respiratory tract infections, gynecologic infections, and other conditions, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.